Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4838526 | 0.98 | KDM4E (0.54) | KDM4ETAAR1HRH1LTA4HPLA2G2A | |
| Hydrochloric Acid SCHEMBL31656522 | 0.98 | KDM4E (0.54) | KDM4ETAAR1HRH1LTA4HPLA2G2A | |
| Hydrochloric Acid SCHEMBL1954121 | 0.98 | KDM4E (0.54) | KDM4ETAAR1HRH1LTA4HPLA2G2A | |
| SCHEMBL2002016 | 0.89 | HRH1 (0.53) | KDM4ETAAR1HRH1NPC1ALDH1A1 | |
| 2-Chloropyridine SCHEMBL1647769 | 0.89 | TDP1 (0.55) | KDM4ETAAR1HRH1LTA4HPLA2G2A | |
| SCHEMBL4190714 | 0.86 | KDM4E (0.50) | KDM4ELTA4HNPC1ALDH1A1CYP2D6 | |
| SCHEMBL29263736 | 0.86 | HRH1 (0.55) | HRH1NPC1ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL15617823 | 0.83 | NPC1 (0.43) | KDM4EHRH1LTA4HNPC1ALDH1A1 | |
| SCHEMBL641980 | 0.82 | — | — | |
| SCHEMBL27333271 | 0.80 | NPC1 (0.44) | KDM4ELTA4HNPC1ALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| EP-2170876-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK HOLDINGS CO LTD (KR) | 2011-12-28 | — | — | EP | claimed |
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2011-02-03 | — | — | US | claimed |
| EP-2170876-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK Holdings Co., Ltd. (KR) | 2010-04-07 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| WO-2009005269-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTINTION AND TREATMENT OF RESTENOSIS COMPRISING ISOXAZOLE DERIVATIVES | SK HOLDINGS CO., LTD. (KR) | 2009-01-08 | — | — | WO | claimed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | claimed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | claimed |
| CN-119841829-A | Compounds for the treatment of PI3K gamma mediated diseases and uses thereof | 中国科学院合肥物质科学研究院 | 2025-04-18 | — | — | CN | disclosed |
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4143189-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-109563073-B | For the treatment of para-5-HT1AReceptor-controlled serotonergic disease-modulating compounds | 诺罗利西斯公司 | 2021-12-07 | — | — | CN | disclosed |
| EP-3475268-B9 | COMPOUNDS FOR TREATING DISORDERS SENSITIVE TO SEROTONINERGIC REGULATION CONTROLLED BY THE 5-HT1A RECEPTORS | NEUROLIXIS (FR) | 2021-04-21 | — | — | EP | disclosed |
| US-6218385-B1 | FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS | HOFFMANN-LA ROCHE INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1074549-A2 | Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors | F. HOFFMANN-LA ROCHE AG (CH) | 2001-02-07 | — | — | EP | disclosed |
| US-5081131-A | Omega-((hetero)alkyl)benz(cd)-indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0252524-A2 | Aryl- and aralkylamide- derivatives of Omega- (substituted-phenyloxy)-alkanoic acids as inhibitors of acyl-coa: cholesterol acyltransferase and pharmaceuticals containing them | WARNER-LAMBERT COMPANY (US) | 1988-01-13 | — | — | EP | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| US-4011324-A | Esters and amides of pyrimido[4,5-b]quinolin-4(3H)-one-2-carboxylic acids as antiulcer agents | PFIZER INC. (US) | 1977-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028506-A1 | Pharmaceutical Composition For Preventintion And Treatment Of Restenosis Comprising Isoxazole Derivatives | PTGIR, GPR119, PTGIS | KDM4E 4564/4885TAAR1 3605/4885HRH1 621/4885 |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | KDM4E 4278/4885TAAR1 4762/4885HRH1 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.